During the past decade, AUSL/IRCCS di Reggio Emilia conducted 48 clinical trials. In the 10-year time frame, 48 clinical trials started and 7 clinical trials were completed, i.e. on average, 14.6% percent of trials that started reached the finish line to date. In the past 5 years, 37 clinical trials started and 5 clinical trials were completed. i.e. 13.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "AUSL/IRCCS di Reggio Emilia" #1 sponsor was "Azienda Unità Sanitaria Locale Reggio Emilia" with 15 trials, followed by "Arcispedale Santa Maria Nuova-IRCCS" with 5 trials sponsored, "Bayer" with 5 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored and "Gruppo Oncologico Italiano di Ricerca Clinica" with 3 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "AUSL/IRCCS di Reggio Emilia" #1 collaborator was "Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta" with 2 trials as a collaborator, "AGO Study Group" with 1 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "AULSS 9 Scaligera di Verona" with 1 trials as a collaborator and "Arcispedale Santa Maria Nuova-IRCCS" with 1 trials as a collaborator. Other collaborators include 39 different institutions and companies that were collaborators in the rest 49 trials.

According to Clinical.Site data, the most researched conditions in "AUSL/IRCCS di Reggio Emilia" are "Breast Cancer" (7 trials), "Colorectal Cancer" (3 trials), "Metastatic Colorectal Cancer" (2 trials), "Actinic Keratoses" (1 trials) and "Acute Non-cardioembolic Ischemic Stroke" (1 trials). Many other conditions were trialed in "AUSL/IRCCS di Reggio Emilia" in a lesser frequency.

Most popular intervention types in "AUSL/IRCCS di Reggio Emilia" are "Drug" (28 trials), "Other" (10 trials), "Procedure" (6 trials), "Device" (5 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Bevacizumab" (3 trials), "Cetuximab" (2 trials), "Irinotecan" (2 trials) and "Radium-223 dichloride (Xofigo, BAY88-8223)" (2 trials). Other intervention names were less common.

The vast majority of trials in "AUSL/IRCCS di Reggio Emilia" are 39 trials for "All" genders, 11 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "AUSL/IRCCS di Reggio Emilia". undefined are not yet recruiting, 21 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in AUSL/IRCCS di Reggio Emilia, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in AUSL/IRCCS di Reggio Emilia, 2 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 14 trials that are defined as “Not Applicable".

AUSL/IRCCS di Reggio Emilia has several departments that took part in Clinical trials: "Arcispedale Santa Maria Nuova; Oncologia" - 17 trials, "Arcispedale Santa Maria Nuova - S.C. Cardiologia" - 7 trials, "AUSL - IRCCS Santa Maria Nuova; U.O. Day Hospital di Oncologia" - 6 trials, "Arcispedale Santa Maria Nuova; Reumatologia" - 5 trials, "Arcispedale Santa Maria Nuova; Dermatologia" - 2 trials